November 29, 2016 - By Dolores Ford · 0 Comments
Idexx Laboratories Inc (NASDAQ:IDXX) institutional sentiment decreased to 1.14 in 2016 Q2. Its down -0.20, from 1.34 in 2016Q1. The ratio turned negative, as 201 institutional investors opened new or increased stock positions, while 150 reduced and sold their stock positions in Idexx Laboratories Inc. The institutional investors in our partner’s database now have: 77.90 million shares, down from 82.81 million shares in 2016Q1. Also, the number of institutional investors holding Idexx Laboratories Inc in their top 10 stock positions increased from 10 to 11 for an increase of 1. Sold All: 27 Reduced: 123 Increased: 122 New Position: 79.
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The company has a market cap of $10.69 billion.
About 75,308 shares traded hands. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 45.99% since April 26, 2016 and is uptrending. It has outperformed by 40.73% the S&P500.
Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on February, 3. They expect $0.51 earnings per share, up 6.25% or $0.03 from last year’s $0.48 per share. IDXX’s profit will be $45.44 million for 58.82 P/E if the $0.51 EPS becomes a reality. After $0.62 actual earnings per share reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -17.74% negative EPS growth.
According to Zacks Investment Research, “IDEXX Laboratories, Inc. is a world leader in providing diagnostic, detection, and information products to the animal health industry as well as quality assurance products and services to the food and water industries.”
Capital Counsel Llc Ny holds 7.66% of its portfolio in IDEXX Laboratories, Inc. for 894,220 shares. Fundsmith Llp owns 4.47 million shares or 6.82% of their US portfolio. Moreover, American Capital Management Inc has 4.99% invested in the company for 649,906 shares. The New York-based Sandhill Capital Partners Llc has invested 3.83% in the stock. Chilton Investment Co Llc, a Connecticut-based fund reported 998,851 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 8 insider sales for $20.49 million net activity.
Ratings analysis reveals 43% of IDEXX Laboratories’s analysts are positive. Out of 7 Wall Street analysts rating IDEXX Laboratories, 3 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $69.50 while the high is $98. The stock’s average target of $82.90 is -30.91% below today’s ($119.99) share price. IDXX was included in 13 notes of analysts from July 24, 2015. As per Monday, March 21, the company rating was maintained by Stifel Nicolaus. The company was maintained on Thursday, August 13 by Stifel Nicolaus. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, October 29. The firm earned “Outperform” rating on Thursday, February 4 by Credit Suisse. The firm earned “Market Perform” rating on Friday, August 28 by Raymond James. The stock has “Hold” rating given by Feltl & Co on Friday, July 24. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by Canaccord Genuity on Thursday, July 23. The company was initiated on Friday, April 1 by CL King. The company was maintained on Wednesday, April 13 by Credit Suisse. The firm has “Buy” rating given on Wednesday, July 20 by Canaccord Genuity.
IDEXX Laboratories, Inc., incorporated in 1983, develops, makes and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Firm operates through three divisions: diagnostic and information technology services and products for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller divisions that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
More notable recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Streetinsider.com which released: “Form 4 IDEXX LABORATORIES INC For: Nov 23 Filed by: CRAIG THOMAS” on November 29, 2016, also Prnewswire.com with their article: “IDEXX Laboratories Announces Departure of Executive Vice President Michael …” published on November 15, 2016, Fool.com published: “IDEXX Laboratories, Inc. Sees More Growth Ahead” on May 02, 2016. More interesting news about IDEXX Laboratories, Inc. (NASDAQ:IDXX) were released by: Fool.com and their article: “Why IDEXX Laboratories, Inc. Reported Higher Today” published on August 02, 2016 as well as Prnewswire.com‘s news article titled: “IDEXX Laboratories to Host 2016 Investor Day” with publication date: August 08, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford